Business Context and Reporting Period
This Form 8-K was filed by Pono Capital Two, Inc. on February 2, 2023, regarding an agreement executed on January 31, 2023. Pono entered into a proposed business combination with SBC Medical Group Holdings Incorporated, a Delaware corporation whose business includes interests related to SBC Medical Group Co., Ltd. in Japan and affiliated service companies and entities.
The transaction is structured as a merger in which Pono’s wholly owned subsidiary will merge with SBC, with SBC surviving. SBC is expected to complete a restructuring before closing to acquire economic or other interests in the relevant Japanese businesses. The Medical Corporations are expected to remain outside the control of SBC or its subsidiaries as required by Japanese law.
Key Financial and Transaction Metrics
- Implied merger consideration: $1.2 billion, subject to adjustments for SBC net working capital, closing net indebtedness, cash, and specified transaction expenses.
- Escrow: Shares equal to 3% of the merger consideration are expected to be placed in escrow for post-closing adjustments.
- Sponsor shares: Pono’s sponsor is expected to receive 1.2 million registered Pono Class A common shares for no additional consideration, subject to the timing provisions in the agreement.
- Equity incentive plan: The proposed post-closing plan is expected to authorize awards equal to 15% of Pono’s issued and outstanding shares immediately after closing.
- Financial results: The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics for SBC or Pono.
- Audited financials: SBC must provide PCAOB-audited GAAP financial statements for the years ended December 31, 2022 and December 31, 2021. Those statements are not included in the filing text provided.
Material Changes Versus the Prior Comparable Period
The filing does not report period-over-period operating or financial results. Its material development is the execution of the merger agreement and related transaction documents; therefore, no comparable-period changes in revenue, earnings, cash flow, margins, debt, or liquidity can be determined from this filing.
Guidance, Outlook, Risks, and Unusual Items
- Closing conditions: The transaction requires approval by Pono and SBC stockholders, required governmental and third-party approvals, SEC completion of its proxy statement review, Nasdaq approval of the merger consideration shares, completion of the restructuring, and satisfaction of customary representations, covenants, and material-adverse-effect conditions.
- Deadlines and termination: Either party may generally terminate if closing has not occurred by September 30, 2023, subject to a possible extension related to Pono’s business-combination deadline. Pono may terminate if required audited financial statements or disclosure and due-diligence materials are not delivered or are materially unsatisfactory.
- Restructuring and regulatory risk: The restructuring must comply with Japanese law, and governmental conditions could materially affect post-closing operations.
- Redemptions and financing: The filing identifies risks from higher-than-expected public-stockholder redemptions, failure to satisfy Nasdaq listing standards, and the potential need for additional capital on uncertain terms.
- Contractual restrictions: Certain SBC stockholders are subject to lock-ups, generally ending upon specified time or share-price conditions, and two-year noncompetition and nonsolicitation restrictions.
- Other unusual items: SBC waived any claim to Pono’s public-stockholder trust account. The merger consideration remains subject to post-closing adjustments based on final working capital, indebtedness, and transaction expenses.
- Outlook: The filing contains transaction-related forward-looking statements but does not provide clear operating or financial guidance for SBC.
Important Facts for Investors to Verify
- Whether the proposed $1.2 billion consideration is reduced by closing debt, transaction expenses, or working-capital adjustments.
- The audited 2021 and 2022 SBC financial statements and whether they materially differ from SBC’s unaudited financial statements.
- Completion and legal structure of the Japanese restructuring, including the absence of control over the Medical Corporations.
- Stockholder approval, SEC proxy review, required regulatory and third-party consents, and Nasdaq listing approval.
- Public-stockholder redemption levels and the amount of cash remaining in Pono’s trust account after the transaction.
- The final share count, dilution from sponsor shares, rollover options and warrants, escrow shares, and the proposed equity incentive plan.
- Whether the transaction closes by the applicable deadline or is terminated because of failed conditions, unsatisfactory diligence, or material adverse effects.